drugset / Trial / NCT04419025

Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease

NCT04419025

Phase 2 Completed 165 enrolled Cambridge Health Alliance
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the efficacy of N-acetylcysteine (NAC) in preventing those with mild or moderate COVID-19 from progressing to severe disease

Timeline

Start
2020-09-23
Primary completion
2021-05-14
Completion
2021-05-14

Drugs

EvaluationDrugModalityDoseRoute
Comparator N-acetylcysteine Small molecule 25 mg/kg Oral
Comparator N-acetylcysteine Small molecule 1200 mg Oral